GeoVax Labs Inc (GOVX:NSD) Analysts see big upside with $6 target

STA Research
by: STA Research

Based on the GeoVax Labs Inc stock forecasts from 1 analysts, the average analyst target price for GeoVax Labs Inc is USD 6.00 over the next 12 months. GeoVax Labs Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of GeoVax Labs Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, GeoVax Labs Inc’s stock price was USD 1.59GeoVax Labs Inc’s stock price has changed by +0.92% over the past week, +0.33% over the past month and -61.78% over the last year.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

What we like

Underpriced compared to book value

The geovax labs stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What we don’t like

Low market capitalization

GeoVax labs stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this geovax labs stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The GeoVax labs stock had negative total cash flow in the most recent four quarters.

Low Earnings Growth

The GeoVax labs stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

The GeoVax labs stock has shown below median revenue growth in the previous 5 years compared to its sector.

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.